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Background: The beneﬁt of statins in the reduction of cardiovascular events was demonstrated in several
placebo-controlled trials. More intensive therapy seems to be associated with greater beneﬁt. Our objective
was to compare different statin doses in the reduction of cardiovascular events and deaths, combining direct
and indirect evidence, through mixed treatment comparisons (MTC).
Methods:We conducted a systematic review in MEDLINE and Cochrane CENTRAL. A random-effects Bayesian
MTC model was used to combine placebo-controlled and direct statin comparison trials. Intensity of statin
doses was classiﬁed according to expected LDL-cholesterol reduction effect: ≤30% as low; 30–40%, interme-
diate, and ≥40%, high. Outcomes evaluated were non-fatal myocardial infarction (MI), stroke, coronary re-
vascularization and coronary, cardiovascular and all-cause death. Inconsistency was assessed with split-
node methodology.
Results: 47 trials (11 with direct statin comparisons) were included. High doses reduced non-fatal MI by 28%
(95% CI: 18%–36%) and by 14% (7%–21%) when compared to low and intermediate doses, respectively. High
doses also diminished revascularization [RR versus low and intermediate doses of 0.81 (0.69–0.95) and 0.88
(0.77–0.99), respectively] and stroke [RR of 0.83 (0.68–0.99) against low doses]. Regimen intensity did not
change death rates (e.g., for all-cause mortality, RRs of 0.93 (0.80–1.06) and 0.98 (0.87–1.08) for high vs.
low and intermediate doses, respectively). No statistical inconsistencies were found in the analyses.
Conclusions: In this study, in which all available evidence from statin trials was simultaneously analyzed, the
beneﬁt of more intensive therapy was restricted to non-fatal events.© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
The beneﬁt of statins in the reduction of major coronary events
and all-cause mortality has been demonstrated in several clinical
trials [1]. Two previous systematic reviews have suggested an asso-
ciation between the extent of LDL cholesterol (LDL-C) reduction and
the magnitude of cardiovascular events prevention [2,3]. Another sys-
tematic review has demonstrated that the increase in the dose of each
statin augments LDL-C reduction [4]. The effects of the same dosage of
individual statins are different: 40 mg of simvastatin has the sameto Alegre, Rua Ramiro Barcelos
il. Tel.: +55 51 33596337; fax:
Ribeiro).
nder the Elsevier OA license. expected LDL-C reduction than 10 mg of atorvastatin, and both are
more potent than 80 mg of pravastatin or ﬂuvastatin, for example.
Considering the above, it is intuitive that a higher statin dose (taking
into account the equipotence among different drugs' dosage schemes)
would be associated with a greater reduction in cardiovascular events.
This hypothesis has been tested in some clinical trials comparing high
versus low dose of statins, and a meta-analysis of such trials, including
circa 40,000 patients, has shown 10% reduction (95% CI: 4%–16%) in
the combined endpoint of myocardial infarction or coronary death,
18% decrease in the incidence of stroke (95% CI: 5%–29%), and a non-
signiﬁcant effect on all-cause mortality [5].
Nonetheless, the number of patients studied in statin trials is
immense, and analyses including all trials comparing statins with
placebo could add in the understanding of the relationship between
statin dose and events reduction by providing indirect evidence. More-
over, results of both direct and indirect evidence could be combined in a
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answer this important question. The objective of this studywas to com-
pare different statin doses (categorized as low, intermediate and high
intensity regimens) in the reduction of cardiovascular events and all-
cause mortality, with three analytic approaches: direct comparison
meta-analysis, indirect comparison meta-analysis, and mixed treat-
ment comparisons, in order to include simultaneously all available
data in the literature.
2. Methods
2.1. Search strategy
In view of the large body of knowledge regarding the effectiveness of statins, the
ﬁrst step in this study was a MEDLINE search for previous systematic reviews evaluat-
ing the use of any statin against placebo or usual care or against another statin. The
most complete paper retrieved was that of Ward et al., which reviewed MEDLINE,
EMBASE, Cochrane CENTRAL and six other electronic databases with the objective of
evaluating the effectiveness of atorvastatin, ﬂuvastatin, pravastatin, rosuvastatin and
simvastatin against placebo, usual care or other statin, in the prevention of cardiovas-
cular events [1]. The search performed in their paper was further applied in our search
strategy for the aforementioned statins only for the time period elapsed since Ward's
review closure (April, 2004). As their analysis did not include lovastatin, the search
for this particular drug also encompassed the period from inception until April, 2004.
The literature search was conducted in MEDLINE and the Cochrane CENTRAL by
two investigators (R.A.R. and S.F.S.). The search strategy for all statins was similar to
the one used by Ward et al. and was performed for the period between April 2004
and November 2008. The following search terms (text words and MeSH) were used
for the MEDLINE search: hydroxymethylglutaryl-coa reductase inhibitors, statins, atorva-
statin, ﬂuvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and a string of words
proposed by Robinson and Dickersin which yields a high sensitivity in the search for
randomized controlled trials [6]. The search for lovastatin in the time period before
April 2004 was similar except for the removal of the names of other statins. The
Cochrane CENTRAL searches were similar, with the omission of the string for clinical
trials. All search strategies are available from authors on request. The MEDLINE search
was restricted to articles in English, Spanish and Portuguese, and included only cita-
tions with abstracts.
During our data analyses, another broad systematic review focusing on statin versus
placebo/no treatment was published [7]. The references of that study, which searched
12 electronic databases until August 2010, were also evaluated according to our eligibility
criteria.
2.2. Outcomes of interest
The outcomes of interest were the following: non-fatal myocardial infarction (MI),
total stroke, coronary heart disease (CHD) mortality, cardiovascular (CV) mortality, all
cause mortality, and coronary revascularization (combination of both surgical and per-
cutaneous). All outcomes were recorded as deﬁned by the authors in the original pub-
lications. In studies where there was no information regarding non-fatal MI but the
total (fatal plus non-fatal) MI was given, the latter was abstracted.
Possible adverse effects of statins, including myalgia, creatine phosphokinase (CPK)
and liver enzymes (either alanine aminotransferase or aspartate aminotransferase) eleva-
tion, were also sought.
2.3. Eligibility criteria
We included any randomized clinical trial comparing atorvastatin, ﬂuvastatin, lova-
statin, pravastatin, rosuvastatin or simvastatin against placebo, usual care or other statin,
in which at least one of the aforementioned outcomes was assessed. Cerivastatin was not
included, since it was withdrawn from the market because of serious adverse events.
Studies in which the effect of statin could not be individualized (that is, administration
in combination with another medication) were not included.
Only studies with duration of 6 months or more and a total number of patients
greater than 100 were included. Studies not assessing prevention of cardiovascular
events (e.g. those investigating cognitive improvement in Alzheimer disease, anti-
inﬂammatory effects in rheumatoid arthritis) were excluded. We also excluded trials
that focused on distinct clinical settings, namely, patients with advanced renal disease,
heart failure, and studies that included exclusively patients of Asian origin (for whom
the response to statins is markedly heightened as compared to Caucasians) [8,9].
2.4. Study selection
The references identiﬁed by the literature searches were scrutinized in three phases.
All studies were initially scanned for relevance by title, and the abstracts of those that
were not excluded at this stage were subsequently appraised. Finally, studies that could
not be excluded according to our eligibility criteria in the abstract review had their full
text retrieved for further evaluation. In parallel, all studies included in the systematicreview by Ward et al. were also assessed for eligibility in full text version according to
our inclusion and exclusion criteria.2.5. Data extraction and assessment of quality
Multiple teams of two reviewers independently abstracted data from included arti-
cles. Disagreements were resolved by consensus and, if necessary, with the opinion of a
third reviewer. The details extracted were the study and patient population characteris-
tics, the type and dosage of statin used, type of comparator (placebo, usual care or another
statin), outcomes assessed, and study quality. The latter used the Cochrane Collaboration
approach, i.e. separately appraising methodological aspects instead of using study quality
scales [10]. The following criteria were evaluated in the assessment of risk of bias: alloca-
tion of treatment concealment, blinding (including patients, caregivers and outcomes as-
sessors), baseline comparability between groups and use of intention to treat analysis.
The outcomes extraction was performed as the following: ﬁrst, the original pub-
lications were examined. If a given original paper did not report results of a selected
outcome, two other sources were evaluated: initially, the supplementary webappen-
dix from the Cholesterol Treatment Trialists' (CTT) Collaboration 2010's systematic
review, and secondly, the systematic review performed by Ward, who had contacted
many authors from the selected trials in order to retrieve unpublished data [1,11].2.6. Statistical analysis
The intensity of regimens was classiﬁed according to the expected LDL-C reduction
for the mean statin dose used in the trials [4]. Regimens with an expected LDL-C reduc-
tion up to 30% (such as ﬂuvastatin 40 mg and pravastatin 20–40 mg) were considered
as low intensity (hereafter also referred to as low dose); between 30% and 40% (atorva-
statin 10 mg, ﬂuvastatin 60–80 mg, lovastatin 30–40 mg, simvastatin 20–40 mg), inter-
mediate intensity (hereafter, also intermediate dose); and over 40% (atorvastatin
20–80 mg, simvastatin 80 mg and rosuvastatin 20 mg), high intensity (hereafter, also
high dose).
The direct evidence was computed with random effects model meta-analysis of
head-to-head statin comparisons. Heterogeneity was evaluated by the means of the
inconsistency test proposed by Higgins, where values below 25% were considered
as low heterogeneity, and above 50%, high heterogeneity [12].
Indirect comparisons (calculated from statin versus no treatment or placebo trials)
were carried out according to the method proposed by Bucher et al. [13]. First, relative
risks of high, moderate and low intensity regimens against placebo or usual care were
calculated through random effects model meta-analysis. Subsequently, the following
formulas were applied in order to retrieve the indirect relative risks and variances of
each pair-wise indirect comparison:
ln RRACð Þ ¼ ln RRABð Þ – ln RRBCð Þ
Var ln RRACð Þ ¼ Var ln RRABð Þ þ Var ln RRBCð Þ:
Bayesian mixed treatment comparison (MTC) meta-analysis is a generalization of
traditional meta-analysis that allows all evidence to be taken into account simulta-
neously (both direct and indirect). It was proposed by Lu and Ades and can be applied
whenever a connected network of evidence is available [14]. The MTC results depend
on the network of evidence and can provide narrower interval estimates. The models
are based on the Bayesian hierarchical framework and are very ﬂexible, allowing the
incorporation of data characteristics like three-arm trials and heterogeneous between-
trials' variability. To analyze the data in this study, we used the MTC random effect
model with homogeneous between-trial variability. The placebo/no treatment arm was
considered the baseline treatment. The goodness-of-ﬁt of the models was measured
through residual deviance and deviance information criteria (DIC). MTC analyses were
performed using both ﬁxed (FE) and random effect (RE) models. Although the number
of parameters in the RE models was higher than in the FE models, the posterior means
of the residual deviance were always much lower, resulting in a lower DIC. The results
shown are from RE models, with homogeneous between-trial variability. The goodness-
of-ﬁt of all MTC models was generally good, considering the residual deviance criteria.
One key assumption of theMTCmodels is the consistency between direct and indirect
evidence, that is, if the information of both sources of evidence are similar enough in
order to be combined. The consistency assumption was checked using the posterior
plots and the Bayesian p-values produced by the node-splitting method proposed
by Dias [15]. In this approach, each node in the network of evidence has its direct,
indirect and MTC components analyzed. The result is considered consistent if the
p value of the analysis is greater than the signiﬁcance level (which was set to 0.01
in the analyses, since the same data are used in multiple comparisons). It should
be noted that the indirect comparison used here is not the one derived by the Bucher
method, but the Bayesian one.
A subgroup analysis was carried out, stratifying the MTC analysis by studied pop-
ulation (primary or secondary prevention).
Traditionalmeta-analysis were carried out in Stata version 10.0 (StataCorp LP, College
Station, Texas) and mixed treatment comparisons, in the softwareWinbugs version 1.4.3
(MRC Biostatistics Unit, Cambridge, UK).
Fig. 2. Geometric distribution of analysis. Network of evidence formed by the three
statin groups and the no statin arm. The numbers accompanying the arrows indicate
the number of trials for that link in the network. Two studies are counted three
times in this ﬁgure, since they included three arms (high and intermediate doses and
placebo) and therefore appear in three analyses.
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3.1. Search results and characteristics of included studies
The electronic databases search yielded 5171 references, from
which 16 full papers were included. The analysis of Ward's systematic
review identiﬁed 31 studies that fulﬁlled our eligibility criteria, total-
izing 47 studies. The study ﬂowchart is shown in Fig. 1. There were six
studies comparing high and moderate dose statins; three evaluating
high versus low statin regimens; and four, seventeen and ﬁfteen stud-
ies comparing high, moderate and low dose regimens versus placebo
or usual care, respectively — two studies presented multiple compar-
isons. The network of evidence is displayed in Fig. 2. Twenty-eight
studies included predominantly (≥85%) secondary prevention pa-
tients (previous MI, stroke or peripheral arterial disease), fourteen
studies included majorly (≥85%) primary prevention patients, and
the remainders were mixed. Mean age in the trials varied from 49
to 74 years old. Average follow up was 3 years, and average pre-
treatment LDL-C was 149 mg/dl. The main characteristics of the
included studies are displayed in Table 1.
The methodological quality of included studies was generally
good. Only three trials did not state if the analyses were carried out
in an intention to treat basis [29,37,39]. Patients and caregivers
were blinded to treatment except for ﬁve trials [19,27,39,48,63]
and the blinding of outcomes assessors were reported except for
ten trials [18,21,24,27,39–41,47,49,57]. The only item with larger
potential to bias was the allocation to study groups: only twenty
studies reported on how it was concealed [16,17,19,22,24,25,27,31,34,
36,43,44,47–49,53,59,60,64,65].
The total number of patients evaluated was 175,232. The out-
comes more commonly reported in the studies were MI (41 studies)
and all cause mortality (39 studies); only 25 trials informed the num-
ber of patients submitted to revascularizations. The number of events
included in the analysis was as follows: 7557 MIs, 4917 strokes,
11,767 revascularization procedures, 12,882 all cause deaths, 5286
CV deaths, and 4969 CHD deaths. The number of patients reporting
myalgia was 11,778; 1823 had liver enzymes elevations of 2–3
times the upper limit of normal, whereas 249 individuals suffered
CPK elevations 10 times above the upper limit of normal.Fig. 1. Flow diagram of the studies' selection process. CHF = Chronic Heart Failure, CKD =
moment of the MEDLINE search. Later, its original publication data, released in 2010, was i3.2. Impact of statin regimen intensity on clinical outcomes
The effects of statins on clinical outcomes are displayed in Table 2.
In the direct comparisons, the only outcome where high dose regi-
men showed statistically signiﬁcant beneﬁt when compared to both
low and moderate dosages was coronary revascularization procedures.
A reduction in non-fatal MI and total strokewas seen in the comparison
between high versus moderate statin-dose, whereas an advantage in
favor of high versus low dose was shown in all cause death. There was
no effect by the high dose regimen in the reduction of cardiovascular
and CHD death. Heterogeneity was generally low in all direct compari-
sons, except for the revascularization (76%) and cardiovascular death
(45%) analyses of the high versus intermediate dose.
The indirect comparisons showed a dose-dependent risk reduc-
tion in MI, where the beneﬁt enlarged with the increase in the regi-
men intensity. Investigating all other outcomes, we found beneﬁt
only in the intermediate versus low dose comparison – where the
number of evaluated patients was larger – for stroke and revascular-
ization. There was no effect of the different dosages in the mortality
outcomes.
In the combination of direct and indirect evidence, by the means
of MTC, the relationship seen for non-fatal MI in the indirect com-
parisons was maintained, although the effect of higher doses was
slightly smaller. As compared to low dose, high and intermediate
dose regimens conferred 28% (95% CrI: 18%–36%) and 15% (95%Chronic Kidney Disease. *The SEARCH study was retrieved as a study protocol in the
ncorporated in the meta-analysis. **Ward et al. [1].
Table 1
Characteristics of included trials.
Study Year Interventions
(mg/day)
Patients
randomized
Patient characteristics Mean age Mean baseline
LDL
Mean follow-up
(yrs)
High-dose vs moderate-dose
3T [16] 2003 A30 vs S35 1093 CVD and dyslipidemia 62.8 202.0 1
A-to-Z [17] 2004 S80 vs S20 4497 ACS 61.0 111.5 2
DALI [18] 2001 A80 vs A10 145 Type 2 diabetes and dyslipidemia 59.4 146.0 0.6
IDEAL [19] 2005 A80 vs S20 8888 Patients aged ≤80 years with deﬁnitive AMI 61.7 121.5 4.8
Mohler [20] 2003 A80 vs A10 240 CVD (stable intermittent claudication) 68.0 125.5 1
Schmermund [21] 2006 A80 vs A10 366 Patients w/no history of CHD and ≥2 CV risk factors 61.5 107.0 1
SEARCH [22] 2010 S80 vs S20 12,064 CHD (previous AMI) 64.2 97.5 6.7
TNT [23] 2005 A80 vs A10 10,001 Clinically evident CHD and recent coronary
revascularization procedure
60.5 97.5 4.9
High-dose vs low-dose
PROVE IT-TIMI [24] 2004 A80 vs P40 4162 CHD (recent ACS) 58.2 106.0 2
REVERSAL [25] 2004 A80 vs P40 502 CHD 56.2 150.0 1.5
SAGE [26] 2007 A80 vs P40 891 Older patients with CHD 72.5 145.5 1
High-dose vs placebo/no treatment
ALLIANCE [27] 2004 A40 vs UC 2442 CHD 61.2 146.5 4.3
DALI [18] 2001 A80 vs placebo 144 Type 2 diabetes and dyslipidemia 59.4 146.0 0.6
JUPITER [28] 2008 R20 vs placebo 17,802 Men ≥55 yrs and women ≥65 yrs w/low LDL-C
and elevated CRP
66.0 108.0 1.9
MARS [29] 1993 L73 vs placebo 270 CHD 58 156.0 2.2
Mohler [20] 2003 A80 vs placebo 234 CVD (stable intermittent claudication) 68.0 125.5 1
SPARCL [30] 2006 A80 vs placebo 4731 Patients with prior stroke or TIA but without known CHD 62.8 133.5 4.9
Moderate-dose vs placebo/no treatment
4S [31] 1994 S30 vs placebo 4444 CHD and moderate hypercholesterolemia 58.0 190.0 5.4
ACAPS [32] 1994 L30 vs placebo 919 Patients 40 to 79 years old, with early carotid atherosclerosis
and moderately elevated LDL-C
61.7 155.5 2.8
AFCAPS/TexCAPS [33] 1998 L30 vs placebo 6605 Men and women with average cholesterol levels 58.7 150.0 5.2
ASCOT-LLA [34] 2003 A10 vs placebo 10,305 Hypertensive, no CHD 63.2 134.0 3.3
ASPEN [35] 2006 A10 vs placebo 2410 Patients with type 2 diabetes with or without a previous AMI 61.1 113.5 4
CARDS [36] 2004 A10 vs placebo 2838 Type 2 diabetes, no clinical CVD 62.0 118.5 4
CCAIT [37] 1994 L40 vs placebo 331 CHD 53.8 172.5 2
CIS [38] 1997 S40 vs placebo 254 CHD and hypercholesterolemia 49.3 166.0 2.3
CLAPT [39] 1999 L40 vs UC 226 CHD 53.9 182.0 2
DALI [18] 2001 A10 vs placebo 145 Type 2 diabetes and dyslipidemia 59.4 146.0 0.6
EXCEL [40] 1991 L40 vs placebo 8245 Primary CVD prevention 55.8 180.0 1
FLARE [41] 1999 F80 vs placebo 834 CHD (successful balloon angioplasty) 60.5 154.0 0.8
FLORIDA [42] 2002 F80 vs placebo 540 CHD (AMI) 60.5 138.5 1
HPS [43] 2002 S40 vs placebo 20,536 CHD, other occlusive arterial disease, or diabetes 64.6 133.0 5
LIPS [44] 2002 F80 vs placebo 1677 CHD (angina or silent ischemia) 60.0 131.5 3.9
LiSA [45] 1999 F60 vs placebo 365 Hyperlipidemia, stable symptomatic CHD 59.8 195.5 1
MAAS [46] 1994 S20 vs placebo 381 Moderate hypercholesterolemia and known CHD 55.3 172.5 4
Mohler [20] 2003 A10 vs placebo 234 CVD (stable intermittent claudication) 68.0 125.5 1
SCAT [47] 2000 S30 vs placebo 460 CHD 61.0 131.0 4
Low-dose vs placebo/no treatment
ALLHAT-LLT [48] 2002 P40 vs UC 10,355 Age ≥55 years and stage 1 or 2 HTN with at least 1 additional
CHD risk factor; hypercholesterolemia
66.4 145.6 4.8
CAIUS [49] 1996 P40 vs placebo 305 Moderately elevated LDL-C, US identiﬁed early atherosclerosis,
no symptomatic CVD
55.0 183.0 3
CARE [50] 1996 P40 vs placebo 4159 Previous AMI, average cholesterol 59.0 139.0 5
GISSI-P [51] 2000 P30 vs UC 4271 CHD (recent MI) 59.9 152.0 2
HYRIM [52] 2005 F40 vs placebo 568 Men aged 40–74 years with hypertension 57.1 151.5 4
KAPS [53] 1995 P40 vs placebo 447 Hypercholesterolemia, with and without CVD 57.4 189.0 3
LIPID [54] 1998 P40 vs placebo 9014 CHD (AMI or unstable angina) 62.0 150.0 6.1
PLAC I [55] 1995 P40 vs placebo 408 CHD 57.0 164.0 3
PLAC II [56] 1995 P30 vs placebo 151 CHD 62.0 166.0 3
PMSG [57] 1993 P30 vs placebo 1062 Primary hypercholesterolemia and ≥2 additional CHD risk factors 55.0 182.5 0.5
PREDICT [58] 1997 P40 vs placebo 695 CHD (successful PTCA) 58.4 156.0 0.5
PREVEND IT [59] 2004 P40 vs placebo 864 Patients with microalbuminuria 51.3 158.0 3.8
PROSPER [60] 2002 P40 vs placebo 5804 Elderly, with or at signiﬁcant risk of CVD 75.4 148.0 3.2
REGRESS [61] 1995 P40 vs placebo 884 CHD 56.2 166.5 2
WOSCOPS [62] 1995 P40 vs placebo 6595 Moderate hypercholesterolemia 55.2 192.0 4.9
A = atorvastatin, F = ﬂuvastatin, L = lovastatin, P = pravastatin, R = rosuvastatin, S = simvastatin, UC = usual care. ACS = acute coronary syndrome, AMI = acute myocardial
infarction, CHD= coronary heart disease, CV = cardiovascular, CVD= cardiovascular disease, CRP = C-reactive protein, HTN= hypertension, TIA = transient, ischemic attack,
US = ultrasonographically.
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tage in favor of high against intermediate dose was 14% (95% CrI:
7%–21%). Analyzing these data separately by type of prevention,
the advantage of higher doses was more pronounced in primaryprevention, although the results were more imprecise than in
secondary prevention (Fig. 3).
High dose regimen also showed a better performance in the re-
duction of stroke when compared to low dose (RR of 0.83, 95% CrI:
Table 2
Direct, indirect and mixed-treatment comparison analyses for clinical outcomes.
Direct comparison I2 Indirect comparison Mixed-treatment
comparison
N RR 95% CI N RR 95% CI RR 95% CI
Non-fatal MI
High vs low 5555 0.87 0.71–1.08 0% 69,352 0.64 0.52–0.78 0.72 0.64–0.82
High vs intermediate 36,056 0.85 0.78–0.92 0% 86,562 0.79 0.65–0.96 0.86 0.79–0.93
Intermediate vs low – – – – 105,208 0.81 0.78–0.84 0.85 0.75–0.95
Total stroke
High vs low 5555 1.00 0.56–1.79 0% 73,960 0.87 0.66–1.14 0.83 0.68–0.99
High vs intermediate 36,056 0.86 0.77–0.96 0% 69,072 1.02 0.78–1.35 0.91 0.80–1.04
Intermediate vs low – – – – 92,614 0.85 0.82–0.87 0.91 0.76–1.09
PCI and CABG
High vs low 4162 0.87 0.76–0.99 – 61,442 0.82 0.47–1.44 0.81 0.69–0.95
High vs intermediate 35,450 0.83 0.73–0.94 76% 70,138 0.94 0.54–1.64 0.88 0.77–0.99
Intermediate vs low – – – – 91,092 0.87 0.81–0.94 0.93 0.79–1.09
Coronary death
High vs low 5053 0.72 0.40–1.29 6% 48,413 1.27 0.84–1.94 0.89 0.69–1.11
High vs intermediate 31,193 0.97 0.88–1.08 0% 45,567 1.46 0.99–2.15 0.98 0.83–1.15
Intermediate vs low – – – – 83,762 0.88 0.75–1.03 0.91 0.72–1.12
Cardiovascular death
High vs low 891 0.40 0.13–1.26 – 45,279 0.91 0.75–1.11 0.86 0.66–1.06
High vs intermediate 13,625 0.89 0.69–1.16 45% 59,995 0.95 0.77–1.18 0.92 0.77–1.10
Intermediate vs low – – – – 90,172 0.96 0.87–1.05 0.93 0.75–1.13
All cause death
High vs low 5555 0.60 0.40–0.91 8% 69,815 1.04 0.96–1.12 0.93 0.80–1.06
High vs intermediate 35,690 0.97 0.90–1.05 14% 85,346 1.08 1.01–1.16 0.98 0.87–1.08
Intermediate vs low – – – – 104,208 0.96 0.86–1.07 0.95 0.83–1.08
N = number of patients; PCI = Percutaneous Coronary Intervention; CABG = Coronary Artery Bypass Surgery; MTC = mixed treatment comparison. The indirect comparison was
calculated by the means of the Bucher method.
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advantage of high dose against both intermediate and low dose in
the reduction of revascularization, seen in the direct comparisons,
was maintained in the MTC [RR of 0.88 (95% CrI: 0.77–0.99) and of
0.81 (95% CrI: 0.69–0.95), respectively]. No association between
statin dose and outcomes reduction was seen in all MTC mortality
analyses.3.3. Adverse events
In the investigation of adverse events, the occurrence of myalgia
did not differ with the different regimens in all performed analyses.
High dose regimens resulted in a greater incidence of elevated liver
enzymes when compared to low and intermediate regimens, which
did not differ from each other, in both direct and mixed treatment
comparisons. CPK elevation results were inconsistent throughout
the analyses (Table 3).Fig. 3.Mixed treatment comparison analysis of myocardial infarction, stratiﬁed by type
of prevention. The total number of events in the primary prevention MTC model was
1394, and in the secondary model, 4591 (the sum of these values is not equal to the
total event number of the MI non-stratiﬁed model, since mixed population studies
were not included in the stratiﬁed analysis).3.4. Consistency of analyses
Posterior plots used to check the consistency assumption dictated
by the MTC models for the MI data are illustrated in Fig. 4. The ﬁve
plots correspond to the ﬁve comparisons, dose regimens against pla-
cebo and each other, where both direct and indirect evidence were
available. The plots suggest that there is no evidence of inconsistency
since the posterior densities of direct and indirect evidence show
good overlap. The smallest Bayesian p-value found was equal to
0.036 for the low dose versus placebo/no treatment comparison. Sim-
ilar plots and p-values were produced for all the MTC models (data
not shown).
4. Discussion
In this study, we evaluated the impact of different intensities of
statin regimens in clinical outcomes and adverse events, with the
inclusion of the totality of evidence published to date — both direct
and indirect data. The most consistent result was the dose-dependent
reduction in non-fatalMI seen in all analyses. In theMTC, high intensity
regimens confer a 27% (95% CrI: 16%–35%) reduction in events in com-
parison to low intensity regimens and a 14% decrease (95% CrI: 6%–21%)
when compared tomoderate regimens, these also being superior to low
intensity schemes (relative risk reduction of 15%, 95% CrI 4%–24%). This
effect wasmore pronounced in the primary prevention setting, in com-
parisons involving high dose regimens. However, it is important to note
that almost one third (in terms of number of patients contributing to
the analysis) of this information is derived from the JUPITER trial
(where a high dose statin – rosuvastatin 20 mg – showed a 65% reduc-
tion of myocardial infarction compared to placebo), which has been
suggested to be an extreme and exaggerated ﬁnding [66,67]. The MTC
results of the revascularization analysis also showed beneﬁts for higher
intensity regimens when compared to lower intensity ones. However,
with the exception of one result showing slightly increased mortality,
more intensive statin regimens showed no effect on mortality –
coronary, cardiovascular and all-cause – in any of the analyses, in-
cluding direct, indirect and combined evidence.
Table 3
Direct, indirect and mixed-treatment comparison analyses for adverse events.
Direct comparison I2 Indirect comparison MTC
N RR 95% CI N RR 95% CI RR 95% CI
Myalgia
High vs low 1393 0.95 0.54–1.67 0% 38,666 1.02 0.81–1.28 1.00 0.63–1.45
High vs intermediate 24,845 1.26 0.92–1.74 63% 66,443 0.99 0.87–1.12 1.14 0.86–1.49
Intermediate vs low – – – – 55,159 1.03 0.85–1.25 0.88 0.54–1.34
Liver enzymes elevation
High vs low 5555 3.19 1.15–8.86 62% 59,769 1.85 0.76–4.46 2.83 1.39–4.93
High vs intermediate 24,845 3.05 1.38–6.75 83% 70,454 1.82 0.70–4.73 3.02 1.75–5.00
Intermediate vs low – – – – 84,663 1.02 0.70–1.47 0.98 0.46–1.76
CPK elevation
High vs low 1393 0.33 0.01–8.14 – 25,769 2.94 0.15–57.76 2.01 0.47–5.02
High vs intermediate 14,864 4.53 1.80–11.40 29% 51,883 6.02 0.31–115.74 4.16 1.47–8.27
Intermediate vs low – – – – 63,306 0.49 0.34–0.70 0.50 0.17–1.13
MTC = mixed treatment comparison. The indirect comparison was calculated by the means of the Bucher method.
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matter of debate in the literature. The American College of Cardiology
guidelines for secondary prevention of patients with previous vascu-
lar diseases suggest a LDL-based approach, where the dosage of statin
is increased until a LDL-C goal (between 70 mg/dl and 100 mg/dl in
the majority of settings) has been reached [68]. Conversely, from a
UK perspective, use of higher doses is not routinely considered for
all subject groups [69]. The disparate ﬁndings of a few major trials
are probably responsible for this inconsistency. Previous ﬁndings on
trials comparing high versus low intensity regimens are controversial,
especially in patients with chronic coronary artery disease. The larger
of these studies, the SEARCH trial, which compared simvastatin 80 mg
versus 20 mg, found a non-signiﬁcant reduction in major vascularFig. 4. Consistency analyses for the MI mixed treatment comparisons. Posterior densities of
(dotted line) and indirect (dashed line) analyses, when each node is split.events [22]. The TNT trial, which evaluated 80 mg and 10 mg of
atorvastatin, showed a statistically signiﬁcant 22% decrease in major
vascular events [23]. Finally, the IDEAL trial, in which the difference
in potency of regimens was more pronounced (atorvastatin 80 mg
versus simvastatin 20 mg) found a 17% reduction in the incidence
of MI (95% CI: 2%–19%), but no effect on the combined endpoint of
major vascular events [19]. On the other hand, the beneﬁt of higher
doses is less debated in acute coronary syndromes. Although the
two trials in this setting did not individually show advantage in
favor of higher doses, the combination of their data resulted in an
odds ratio of 0.75 (95% CI: 0.61–0.93) for all-cause mortality and of
0.84 (95% CI: 0.72–0.97) for the combined end-point of myocardial
infarction and coronary death [70].the mean log-relative risk calculated using the full MTC model (solid line), and direct
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lower doses has been compiled by the means of meta-analysis by
Mills et al. [5]. In that paper, which included 10 trials and 40,000 pa-
tients, there was no difference in all-cause or cardiovascular mortality.
Higher doses were more effective than lower doses in the reduction of
non-fatal MI (RR 0.82, 95% CI 0.76–0.89), total stroke (RR 0.86, 95% CI,
0.77–0.96), and the combined endpoint of MI plus coronary death (RR
0.90, 95% CI, 0.84–0.96). Although these results are not directly compa-
rable to ours, since that study divided statins in only 2 groups and did
not combine direct with indirect evidence, they are similar to ours,
showing an advantage in higher doses only for non-fatal events (con-
sidering that the beneﬁt in the combined endpoint of MI plus coronary
death is mostly driven by non-fatal MI).
At ﬁrst glance, our results are somewhat conﬂicting with the recent
update of the Cholesterol Treatment Trialists' (CTT) Collaboration sys-
tematic review [71]. In that paper, which evaluated the relationship
between intensity of LDL-C reduction and major vascular events,
the authors included large (N>1000) trials comparing either high
versus low intensity statin regimens (5 trials) or statin against place-
bo (21 trials). Although their analysis focused on LDL-C reduction,
whose magnitude was shown to be related to events reduction, the
authors concluded that more intensive statin therapy proved beneﬁ-
cial, suggesting that newer andmore potent statins should be used in
order to achieve greater beneﬁts. The inference of a greater beneﬁt
from more potent regimens was probably based on the results of
the ﬁve direct statin comparison trials included, where LDL-C reduc-
tion was more pronounced with high dose statins. However, the
investigators neglected the fact that, in the statin versus placebo
studies, the greater LDL-C reductions were achieved by moderate
intensity regimens: 69 mg/dl in 4S (mean simvastatin dose of 30 mg)
and 50 mg/dl in HPS (mean simvastatin dose of 40 mg). Actually,
among the 10 trials with greatest LDL-C reductions (4S, HPS, ALLIANCE,
CARDS, JUPITER, WOSCOPS, Post CABG, ASCOT-LLA, PROSPER and
CARE), only one used a statin regimen that could be considered
high intensity (JUPITER), whereas three of them evaluated prava-
statin 40 mg, a low intensity regimen. It seems more appropriate to
assume that the patients' baseline characteristics and the design of
the trials had a stronger inﬂuence on the results than the potency
of statins used.
The methodological approach we used is innovative in two senses.
First, the division of statins in three groups of regimen intensity seems
more appropriate than only two, considering the large number of
drugs and dosages available in the market, and the wide spectrum of
statin potency. Second, to our knowledge, this is the ﬁrst article on
this topic to perform dose comparisons using direct, indirect and MTC
approaches. The MTC approach allowed us to (1) incorporate all avail-
able evidence, (2) estimate the treatment effects where direct evidence
was not available (in the intermediate versus low dose comparison),
and (3) enhance precision of the estimates (considering the narrower
conﬁdence intervals, when compared to direct evidence analysis only).
At ﬁrst glance, one could argue that some of the MTC results sug-
gest inconsistencies, considering that a few of theMTC's RR are not in
between the direct and indirect RR estimates. This ﬁndingwould be a
concern if the analysis included only three interventions. However,
the network of evidence is more complex, as depicted in Fig. 2, and
includes four interventions. Therefore, e.g. the MTC RR of stroke
(0.83) in the comparison between high and low dose is not situated
between the direct (1.00) and indirect estimate (0.87), since a more
intricate network is acting in the MTC. The statistical analysis of in-
consistency conﬁrms the adequacy of using MTC to gather all data
(Fig. 4): the lowest p-value of all analyses was 0.036, higher than
the signiﬁcance value of 0.01 (which should be used in situations of
multiple analyses with the same data). Moreover, the MTC approach
aided in solving some discrepancies seen in the other two analytic
approaches: e.g. the direct evidence suggested a greater difference
between high and intermediate doses than between high and lowdoses in revascularization; this relationship was inverted when the
MTC was used.
Some limitations of our study should be mentioned. First, we used
the literature search from a previous systematic review for trials pub-
lished before 2004 instead of performing a primary search [1]. How-
ever, we also checked the references from another broad systematic
review, with a search period longer than ours (until August 2010),
and no additional trial fulﬁlled our eligibility criteria. Therefore, it is
not likely that a relevant trial was left aside from our analyses. Sec-
ondly, the cut-points applied to deﬁne a treatment intensity as high,
intermediate or low were based on expected LDL-C reduction, and it
is possible that, altering these cut-points, the observed differences
in treatment effects could change. Moreover, we used aggregated
data from trials, and not patient-level data. Considering that the clas-
siﬁcation of the statin regimen was based on the mean dose used in
trial, and some trials had great variability in the dose prescribed
(such as in ALLIANCE, where the atorvastatin dose ranged from 10
to 80 mg), the use of patient-level data would be helpful in classifying
all available data into the correct regimen intensity. Finally, not all tri-
als reported all outcomes (especially stroke and revascularization),
which has been recognized as a source of bias, since underreported
outcomes within a trial might more likely be the ones for which the
results were negative [72,73]. Therefore, the differences between
treatments might be smaller than the ones found in our analysis.
In conclusion, our systematic review based on aggregate data on
175,232 individuals from 46 studies, has found a protective effect
for higher intensity dosages of statins for non-fatal events, but no
beneﬁt on all-cause and CHD mortality. Most of this effect is partly
achieved by the widely prescribed intermediate intensity regimens
of simvastatin 40 mg, for instance. The use of newer and more potent
statins could add some small beneﬁt on non-fatal events, but current-
ly at a considerable additional cost, and a potential increase in liver
transaminase elevations.
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